534 related articles for article (PubMed ID: 27080976)
21. Adverse outcomes of proton pump inhibitors in patients with chronic kidney disease: The CKD-REIN cohort study.
Liabeuf S; Lambert O; Metzger M; Hamroun A; Laville M; Laville SM; Frimat L; Pecoits-Filho R; Fouque D; Massy ZA; Jacquelinet C; Stengel B;
Br J Clin Pharmacol; 2021 Jul; 87(7):2967-2976. PubMed ID: 33368448
[TBL] [Abstract][Full Text] [Related]
22. Proton pump inhibitors use and risk of chronic kidney disease and end-stage renal disease.
Vengrus CS; Delfino VD; Bignardi PR
Minerva Urol Nephrol; 2021 Aug; 73(4):462-470. PubMed ID: 33769018
[TBL] [Abstract][Full Text] [Related]
23. Association of Proton Pump Inhibitors Usage with Risk of Pneumonia in Dementia Patients.
Ho SW; Teng YH; Yang SF; Yeh HW; Wang YH; Chou MC; Yeh CB
J Am Geriatr Soc; 2017 Jul; 65(7):1441-1447. PubMed ID: 28321840
[TBL] [Abstract][Full Text] [Related]
24. Renal Transplant Acute Rejection with Lower Mycophenolate Mofetil Dosing and Proton Pump Inhibitors or Histamine-2 Receptor Antagonists.
Patel KS; Stephany BR; Barnes JF; Bauer SR; Spinner ML
Pharmacotherapy; 2017 Dec; 37(12):1507-1515. PubMed ID: 28976570
[TBL] [Abstract][Full Text] [Related]
25. Retrospective analysis of the effect of acid-suppressant therapy on clinicopathologic parameters of cats with chronic kidney disease.
Gould E; Klos J; Price J; Harris T; Vaden S; Tolbert MK
J Feline Med Surg; 2018 Jun; 20(6):520-527. PubMed ID: 28703633
[TBL] [Abstract][Full Text] [Related]
26. Acid suppressants use and the risk of dementia: A population-based propensity score-matched cohort study.
Wu CL; Lei WY; Wang JS; Lin CE; Chen CL; Wen SH
PLoS One; 2020; 15(11):e0242975. PubMed ID: 33253311
[TBL] [Abstract][Full Text] [Related]
27. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
[TBL] [Abstract][Full Text] [Related]
28. Proton Pump Inhibitor Use, H
Paik JM; Rosen HN; Gordon CM; Curhan GC
Calcif Tissue Int; 2018 Oct; 103(4):380-387. PubMed ID: 29754277
[TBL] [Abstract][Full Text] [Related]
29. The Effect of Proton Pump Inhibitor Use on the Course of Kidney Function in Patients with Chronic Kidney Disease Stages G3a to G4.
Giusti S; Lin Y; Sogbetun F; Nakhoul N; Liu S; Shi L; Batuman V
Am J Med Sci; 2021 Nov; 362(5):453-461. PubMed ID: 34033809
[TBL] [Abstract][Full Text] [Related]
30. Gout and the risk of advanced chronic kidney disease in the UK health system: a national cohort study.
Stack AG; Johnson ME; Blak B; Klein A; Carpenter L; Morlock R; Maguire AR; Parsons VL
BMJ Open; 2019 Aug; 9(8):e031550. PubMed ID: 31462487
[TBL] [Abstract][Full Text] [Related]
31. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis.
Bajaj JS; Ratliff SM; Heuman DM; Lapane KL
Aliment Pharmacol Ther; 2012 Nov; 36(9):866-74. PubMed ID: 22966967
[TBL] [Abstract][Full Text] [Related]
32. Safety of Concomitant Metformin and Proton Pump Inhibitor Use: A Population Retrospective Cohort Study.
Chen CB; Lin M; Eurich DT; Johnson JA
Clin Ther; 2016 Jun; 38(6):1392-1400. PubMed ID: 27061884
[TBL] [Abstract][Full Text] [Related]
33. Association of Serum Ig Free Light Chains with Mortality and ESRD among Patients with Nondialysis-Dependent CKD.
Ritchie J; Assi LK; Burmeister A; Hoefield R; Cockwell P; Kalra PA
Clin J Am Soc Nephrol; 2015 May; 10(5):740-9. PubMed ID: 25825483
[TBL] [Abstract][Full Text] [Related]
34. Short-term change in kidney function and risk of end-stage renal disease.
Turin TC; Coresh J; Tonelli M; Stevens PE; de Jong PE; Farmer CK; Matsushita K; Hemmelgarn BR
Nephrol Dial Transplant; 2012 Oct; 27(10):3835-43. PubMed ID: 22764191
[TBL] [Abstract][Full Text] [Related]
35. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis.
Nochaiwong S; Ruengorn C; Awiphan R; Koyratkoson K; Chaisai C; Noppakun K; Chongruksut W; Thavorn K
Nephrol Dial Transplant; 2018 Feb; 33(2):331-342. PubMed ID: 28339835
[TBL] [Abstract][Full Text] [Related]
36. Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients.
Lee HJ; Lee H; Oh SH; Park J; Park S; Jeon JS; Noh H; Han DC; Kwon SH
PLoS One; 2018; 13(9):e0203878. PubMed ID: 30212538
[TBL] [Abstract][Full Text] [Related]
37. Proton Pump Inhibitors and the Kidney: Implications of Current Evidence for Clinical Practice and When and How to Deprescribe.
Al-Aly Z; Maddukuri G; Xie Y
Am J Kidney Dis; 2020 Apr; 75(4):497-507. PubMed ID: 31606235
[TBL] [Abstract][Full Text] [Related]
38. Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression.
Bowe B; Xie Y; Xian H; Balasubramanian S; Al-Aly Z
Kidney Int; 2016 Apr; 89(4):886-96. PubMed ID: 26924057
[TBL] [Abstract][Full Text] [Related]
39. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure.
Stevens V; Dumyati G; Brown J; Wijngaarden E
Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1035-42. PubMed ID: 21833992
[TBL] [Abstract][Full Text] [Related]
40. Constipation and Incident CKD.
Sumida K; Molnar MZ; Potukuchi PK; Thomas F; Lu JL; Matsushita K; Yamagata K; Kalantar-Zadeh K; Kovesdy CP
J Am Soc Nephrol; 2017 Apr; 28(4):1248-1258. PubMed ID: 28122944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
